Lab77 Peptides is not affiliated with the cited publications or databases.
The obesity pharmacotherapy landscape shifted dramatically when Phase 2 data for Retatrutide emerged in 2023
Permanent treatment discontinuation rates due to TEAEs were very low with 0.7% (1 participant, 2 mg), 0.7% (1 participant, 4 mg), 1.4% (2 participants, 6 mg) and 0% (placebo)
Designed strictly for laboratory research use, proper handling ensures 99%+ purity throughout your protocol: Reconstitution: Gently dissolve with a sterile solvent (such as bacteriostatic water) to create a uniform solution
However, the overall side effect profile in clinical trials was generally comparable to tirzepatide, with gastrointestinal events being the most common and dose-limiting factor
I'm very excited to continue my weight loss through to 2026